ModernMedicine Resource Center More Topics

Video

Sulcus-to-sulcus suture technique offers solution for silicone oil use in aphakic eyes with iris loss

Retention sutures placed sulcus-to-sulcus in the iris plane are effective for keeping the silicone oil out of the anterior chamber.

Retina Treatments

Ophthalmologists’ role key to mitigating burden of diabetic eye diseasePreserving vision in patients with diabetes requires ophthalmologists to be aware of the importance of reinforcing preventive strategies, maintaining communication with internists/diabetologists, and keeping up to date with current treatment approaches.
Anti-VEGF agent therapy rivals laser for macular edema in BRVOPatients treated with aflibercept intravitreal injections for macular edema associated with branch retinal vein occlusion had a significantly greater decrease in central retinal thickness and significantly greater improvement in vision compared with laser at the end of the 52-week VIBRANT trial.
Study suggests ranibizumab superior for edema secondary to BRVOHead-to-head randomized controlled study found ranibizumab to show more favorable results to treating macular edema secondary to BRVO than a single dose of dexamethasone.
Genotype influences response to AREDS formulationAn analysis of independent data published in AREDS Report 38 shows that the response of patients with moderate to advanced age-related macular degeneration (AMD) to treatment with zinc or the Age-Related Eye Disease Study (AREDS) formulation varied substantially based on genotype.
Eylea far better for DME patients, NIH study reports
Eylea far better for DME patients, NIH study reportsAflibercept is reportedly superior to ranibizumab and bevacizumab when treating some patients with diabetic macular edema (DME), according to a National Institutes of Health (NIH)-sponsored clinical trial.
Questions remain if anti-VEGF therapy influences atrophy in neovascular AMD
Questions remain if anti-VEGF therapy influences atrophy in neovascular AMDAnalysis of the Harbor Study data could not definitively answer the question about whether anti-vascular endothelial growth factor (VEGF) therapies influence the development of atrophy in patients with neovascular age-related macular degeneration (AMD). However, investigators did find that the visual acuity (VA) continued to improve in patients treated with monthly and as-needed drug regimens and that certain risk factors can predict development of atrophy, according to Srinivas Sadda, MD.